Option Care Health (NASDAQ:OPCH) Releases FY 2025 Earnings Guidance

Key Points

• Option Care Health (NASDAQ:OPCH) provided their FY 2025 earnings guidance with an EPS forecast of 1.650-1.720, surpassing the consensus estimate of 1.335.
• The company's revenue guidance is set at $5.5 billion-$5.7 billion, aligning with the consensus revenue estimate of $5.5 billion.
• Option Care Health reported a 16.3% year-over-year increase in quarterly revenue, achieving $1.33 billion this quarter compared to analyst expectations of $1.26 billion.

Option Care Health (NASDAQ:OPCH - Get Free Report) issued an update on its FY 2025 earnings guidance on Wednesday morning. The company provided earnings per share guidance of 1.650-1.720 for the period, compared to the consensus earnings per share estimate of 1.335. The company issued revenue guidance of $5.5 billion-$5.7 billion, compared to the consensus revenue estimate of $5.5 billion.

Option Care Health Price Performance

NASDAQ OPCH traded down $1.09 on Friday, reaching $28.26. The company had a trading volume of 1,842,798 shares, compared to its average volume of 1,516,555. The company has a quick ratio of 1.00, a current ratio of 1.52 and a debt-to-equity ratio of 0.81. The stock has a market capitalization of $4.59 billion, a PE ratio of 19.62, a price-to-earnings-growth ratio of 1.79 and a beta of 0.79. The firm's 50 day moving average price is $31.04 and its 200 day moving average price is $31.98. Option Care Health has a 12 month low of $21.39 and a 12 month high of $35.53.

Option Care Health (NASDAQ:OPCH - Get Free Report) last posted its earnings results on Wednesday, July 30th. The company reported $0.41 earnings per share for the quarter, topping analysts' consensus estimates of $0.40 by $0.01. Option Care Health had a net margin of 3.93% and a return on equity of 17.53%. The firm had revenue of $1.42 billion for the quarter, compared to the consensus estimate of $1.35 billion. During the same period in the previous year, the firm posted $0.30 EPS. The business's quarterly revenue was up 15.4% on a year-over-year basis. As a group, equities analysts predict that Option Care Health will post 1.22 earnings per share for the current year.

Analyst Ratings Changes

OPCH has been the topic of a number of research reports. Citigroup restated an "outperform" rating on shares of Option Care Health in a report on Thursday. UBS Group raised shares of Option Care Health from a "neutral" rating to a "buy" rating and raised their price objective for the stock from $38.00 to $40.00 in a research note on Wednesday, April 30th. Barrington Research restated an "outperform" rating and issued a $38.00 target price on shares of Option Care Health in a research note on Thursday, July 10th. Finally, JMP Securities upped their target price on shares of Option Care Health from $36.00 to $38.00 and gave the stock a "market outperform" rating in a research note on Thursday. One research analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company's stock. According to MarketBeat.com, Option Care Health currently has a consensus rating of "Moderate Buy" and a consensus price target of $35.75.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the company. Royal Bank of Canada increased its stake in Option Care Health by 20.7% during the 1st quarter. Royal Bank of Canada now owns 231,161 shares of the company's stock valued at $8,078,000 after purchasing an additional 39,661 shares in the last quarter. AQR Capital Management LLC increased its stake in Option Care Health by 162.6% during the 1st quarter. AQR Capital Management LLC now owns 41,633 shares of the company's stock valued at $1,450,000 after purchasing an additional 25,777 shares in the last quarter. Finally, Empowered Funds LLC acquired a new position in Option Care Health during the 1st quarter valued at approximately $208,000. Institutional investors own 98.05% of the company's stock.

About Option Care Health

Option Care Health, Inc offers home and alternate site infusion services in the United States. The company provides anti-infective therapies; home infusion services to treat heart failures; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; immunoglobulin infusion therapies for the treatment of immune deficiencies; and treatments for chronic inflammatory disorders, including crohn's disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders.